The laboratory was jointly established by the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Capital Medical University; Beijing Yaquanneng Biotechnology Co., Ltd.; and TRANSN IOL Technology Co.,Ltd. Dedicated to the fields of regenerative medicine and cellular therapeutics, the laboratory advances interdisciplinary innovation in key technologies from multiple dimensions.

In terms of disease mechanisms, it focuses on elucidating the shared molecular mechanisms and critical pathogenic pathways underlying aging and degenerative disorders, particularly in cellular metabolism and signal transduction. In frontier technology development, the laboratory leverages artificial intelligence to intelligently analyze cell differentiation data and predict gene targets, while integrating synthetic biology approaches to optimize cellular regeneration strategies. In the area of medical-engineering integration, it seeks to achieve breakthroughs across the entire industrial chain by developing independently innovative foundational technologies, such as novel cell culture systems and efficient drug delivery platforms, thereby reducing production costs while improving therapeutic efficacy and safety. For specific indications, the laboratory also explores innovative applications of cell transplantation, gene therapy, and related approaches to repair damaged tissues and restore organ function.

At the same time, it is building an intelligent laboratory platform based on the architecture of “foundation models + domain-specific models + biological knowledge graphs,” empowering new drug development, personalized therapy, and intelligent applications in traditional Chinese medicine.

https://www.pumc.edu.cn/PLATROTM/ynptjd/sbj/21f51de098a44917a2ef03fcc5e91631.htm